Skip to content

Author

Yu-Bo Zhou

We have 5 of 213 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Oct 2026

From Ubiquitination to Proteasome-Directed Recruiting: Emerging Mechanisms and Therapeutic Potential in Targeted Protein Degradation.

Targeted protein degradation has transformed drug discovery by enabling selective elimination of disease-associated proteins. Beyond classical E3 ligase-recruiting degraders, emerging proteasome-directed strategies seek to recruit targets directly to the proteasome, potentially bypassing E3 ligase dependency and ubiqui...

Yao-Li Shi, Jia-Yi Ma, Yu-Tong Tu et al. · 0 citations
Sep 2026

Structure-Based Optimization of 2-Aminopyrimidine Derivatives as Potent Multi-target FLT3/CHK1/IRAK4 Inhibitors for Acute Myeloid Leukemia.

The efficacy of FLT3 inhibitors is limited by resistance. Co-inhibiting FLT3 and CHK1 can overcome FLT3i resistance, and IRAK4 signaling contributes to leukemic cell survival in FLT3-mutant acute myeloid leukemia (AML). We discovered a novel series of 2-aminopyrimidine derivatives as potent multi-target FLT3/CHK1/IRAK4...

Xue-Mei Li, Kai-Long Jiang, Lu-Yao Zhang et al. · 0 citations
Sep 2026

Design, synthesis, and structural optimization of novel pan-KRAS degrader for the treatment of KRAS-mutant pancreatic cancer.

KRAS, a frequently mutated oncogene, has been demonstrated to harbor multiple mutant variants. Although KRAS G12C inhibitors have been successfully approved for clinical use, their efficacy remains limited by acquired resistance and narrow patient eligibility. Here, we leveraged the proteolysis-targeting chimera (PROTA...

Shen-Xin Zeng, Yi-Qing Zhao, Yan-Qing Liu et al. · 0 citations
Aug 2026

Discovery of BRD9 PROTAC/IMiD Bifunctional Molecules as Potent Therapeutics for Hematologic Malignancies.

Bifunctional BRD9 PROTAC/immunomodulatory drug (IMiD) degraders engineered to simultaneously eliminate BRD9 and IKZF1 validate this dual-targeting PROTAC/IMiD strategy as an effective approach to overcoming the limitations of selective BRD9 degraders, underscores its therapeutic potential in hematologic malignancies.

Hai-Ting Duan, Ruo-Xin Chen, Jing-Yu Zhang et al. · 0 citations
Open access Aug 2026

Discovery of a Potent and Selective KRAS G12D Degrader based on PROTAC Degradation.

This work designed and synthesized 20 novel KRAS G12D PROTACs based on the MRTX1133 derivative and found that compound VI-1 exhibited significant KRAS G12D degradation activity in PANC-0203 cells, achieving 69% effective degradation at 10 μM.

Lili Jiang, Wenyan Yang, Yan-Qing Liu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.